KCCOP Protocol Summary

 Home | Print Summary

The summary below serves as a brief review of the treatment plan and eligibility for the protocol.
This summary is not intended to be used in place of the full protocol.
Members may follow the "Full Protocol" link or contact KCCOP for complete protocol information.

 

Full Protocol

(members only)

 

Consent Form

 

HIPAA

SWOG S0325 - "A Phase IIB Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase"

 

Treatment Plan    (Supplied Drug:  Dasatinib)

 

All Tx Arms - Continue x 12 mos or until other protocol criterion met.  Arms 1 & 3 may continue protocol therapy past 12 mos at investigator's discretion, until 5 yrs from initial regist.

 

Arm 1

Imatinib:  400mg, PO, QD w/food (x 12 mos or other protocol criterion met)

 

Arm 2   (Closed effective 1/10/07)

Imatinib:  400mg, PO, BID w/food

 

Arm 3

Dasatinib:  100mg, PO, QD

 

Eligibility